Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement
Article Dans Une Revue Dermatology and Therapy Année : 2022

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study

Dates et versions

hal-04076820 , version 1 (21-04-2023)

Identifiants

Citer

Andrew Alexis, Marjolein de Bruin-Weller, Stephan Weidinger, Weily Soong, Sebastien Barbarot, et al.. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study. Dermatology and Therapy, 2022, 12 (3), pp.771-785. ⟨10.1007/s13555-022-00694-1⟩. ⟨hal-04076820⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

More